Skip to Main Content

Paper Details

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Ann Oncol
18
2021
AURKA, Agilent-44K microarrays, BPI, CONCLUSIONS SET2,3, ERBB2, ESR1, HER2, HR, PATIENTS, PGR, PR, Patients, RCB, RNA4, SET2, SET2,3, SETER, U133A microarrays, anthracycline, breast cancer, cancer, cancers, estrogen, hormone receptor, hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer, human epidermal growth factor receptor 2, human epidermal growth factor receptor 2 (HER2)-negative, luminal subtypes, patients, progesterone, progesterone receptors, stage II-III, stage II-III breast cancer, taxane, tumor
Author NameAffiliation
Christina YauUniversity of California san francisco
Christina YauUniversity of California san francisco
Claudine IsaacsGeorgetown University
Lajos PusztaiYale University School of Medicine
Rita NandaUniversity of Chicago
Richard B SchwabUniversity of California
Donald A BerryThe University of Texas MD Anderson Cancer Center
Laura J Van't VeerUniversity of California san francisco
William F SymmansThe University of Texas MD Anderson Cancer Center
  • 1 - 9

Datasets

Release 1.2